Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RB1 | P06400 | 7/20 | 0.70 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.61 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.55 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | CDC42 | P60953 | 1/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13748402 | 0.95 | RB1 (0.68) | RB1BRD3SIRT1SIRT2CYP2D6 | |
| SCHEMBL13624632 | 0.84 | RB1 (0.65) | RB1BRD3SIRT1SIRT2CYP2D6 | |
| SCHEMBL13780949 | 0.83 | RB1 (0.60) | RB1BRD3SIRT1SIRT2CYP2D6 | |
| SCHEMBL4144167 | 0.82 | CYP2D6 (0.73) | RB1BRD3SIRT1SIRT2CYP2D6 | |
| SCHEMBL25293118 | 0.82 | RB1 (0.62) | RB1BRD3SIRT1SIRT2CYP2D6 | |
| SCHEMBL4196304 | 0.82 | RB1 (0.62) | RB1BRD3SIRT1SIRT2CYP2D6 | |
| SCHEMBL25248626 | 0.82 | RB1 (0.62) | RB1BRD3SIRT1SIRT2CYP2D6 | |
| SCHEMBL4196380 | 0.81 | RB1 (1.00) | RB1BRD3SIRT1SIRT2CYP2D6 | |
| Hydrochloric Acid SCHEMBL4160613 | 0.81 | RB1 (0.63) | RB1BRD3SIRT1SIRT2CYP2D6 | |
| SCHEMBL16433477 | 0.80 | ALOX15 (0.71) | BRD3SIRT1SIRT2GAACASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1070051-B1 | PROCESS FOR THE PRODUCTION OF R-(+)-6- CARBOXAMIDO- 3-N- METHYLAMINO- 1,2,3,4- TETRAHYDROCARBAZOLE | VERNALIS DEV LTD (GB) | 2015-06-03 | — | — | EP | disclosed |
| WO-2011095803-A1 | HPLC METHOD FOR ANALYZING FROVATRIPTAN | GENERICS [UK] LIMITED (GB) | 2011-08-11 | — | — | WO | disclosed |
| US-20090156621-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-06-18 | — | — | US | disclosed |
| US-7351733-B2 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1070051-A1 | PROCESS FOR THE PRODUCTION OF R-(+)-6- CARBOXAMIDO- 3-N- METHYLAMINO- 1,2,3,4- TETRAHYDROCARBAZOLE | Vernalis Limited (GB) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999054302-A1 | PROCESS FOR THE PRODUCTION OF R-(+)-6- CARBOXAMIDO- 3-N- METHYLAMINO- 1,2,3,4- TETRAHYDROCARBAZOLE | VERNALIS LIMITED (GB) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156621-A1 | HCV INHIBITORS | HAVCR2, MAVS, EIF2AK2 | RB1 4460/4885BRD3 4059/4885SIRT1 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.